Clinical Trials Logo

Clinical Trial Summary

This Phase 1 clinical trial is aimed to evaluate the safety and immunogenicity of 3 doses of 5 sequentially escalating dosages of a candidate vaccine against Shigella sonnei (1790GAHB vaccine) administered by intramuscular route in healthy adults (18 to 45 years of age at enrollment). The safety profile of the 1790GAHB vaccine is evaluated in comparison to that of placebo (GAHB-Placebo), constituted by an aluminum hydroxide suspension having the same concentration as study vaccine formulations. A total of 50 eligible subjects will be assigned to one of five sequential cohorts of 10 subjects each.

Within each cohort, in an observer-blind fashion, subjects will be randomized to receive three vaccinations, four weeks apart, of either 1790GAHB vaccine (at five antigen concentrations) or GAHB placebo. A Data Safety Monitoring Board will be in place to receive a summary of all safety data obtained during one week follow-up post-first vaccination with the lower dose. Based on evaluation of the safety data, the Data Safety Monitoring Board will make a recommendation, as to whether the next cohort should be vaccinated with higher antigen concentration or not.

Expected duration of the study for an individual subject is 9 months. Each subject will be followed-up for 6 months after the 3rd vaccination.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02017899
Study type Interventional
Source GSK Vaccines Institute For Global Health S.r.l.
Contact
Status Completed
Phase Phase 1
Start date February 2014
Completion date March 2015

See also
  Status Clinical Trial Phase
Completed NCT02797236 - SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT04056117 - A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Phase 1/Phase 2
Not yet recruiting NCT05959616 - Shigella Sonnei 53G Human Infection Study in Kenyan Adults Phase 1
Completed NCT02445963 - Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Phase 1
Not yet recruiting NCT05961059 - InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia Phase 1
Completed NCT00485134 - Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Phase 1/Phase 2
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT02034500 - Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Phase 1
Completed NCT01509846 - Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Phase 1
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Withdrawn NCT01399424 - Shigella Sonnei OSPC-rDT Conjugate Vaccine Phase 1
Completed NCT00800930 - Therapeutic Induction of Endogenous Antibiotics Phase 2
Completed NCT00368316 - Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Phase 3
Recruiting NCT05182749 - Safety and Efficacy of the Bacteriophage Preparation, ShigActiveâ„¢, in a Human Experimental Model of Shigellosis Phase 1/Phase 2
Completed NCT02388009 - Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Phase 1
Completed NCT01069471 - Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Phase 1
Completed NCT02646371 - Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Phase 2
Recruiting NCT05156528 - Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Phase 3
Completed NCT03854929 - Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery Phase 4
Recruiting NCT05121974 - Tebipenem Trial in Children With Shigellosis Phase 2